What is the ROCE (Return on Capital Employed) of Passage Bio this year?
The ROCE of Passage Bio is -0.93 undefined this year.
Passage Bio ROCE 2024
Passage Bio ROCE
-0.93
Ticker
PASG
ISIN
US7027121000
WKN
A2P0EQ
In 2024, Passage Bio's return on capital employed (ROCE) was -0.93, a 34.63% increase from the -0.69 ROCE in the previous year.
Passage Bio Aktienanalyse
What does Passage Bio do?
Passage Bio Inc is a biopharmaceutical company focused on the treatment of rare genetic diseases. The company is headquartered in Pennsylvania, USA and was founded in 2018. The beginnings of Passage Bio Inc can be traced back to the work of the Penn Medicine Gene Therapy Program, which has been focusing on researching gene therapies for rare diseases for many years. In 2018, the company was finally founded to bring the research results to the market and help patients with rare diseases. Passage Bio's business model is to develop and market gene therapies based on AAV (Adeno-associated viruses). These viruses are injected into the body and are used to transport healthy genes into cells to replace defective or diseased genes. This can restore the production of missing or damaged proteins, which can contribute to symptom relief and disease cure. The company specializes in developing gene therapies for rare, monogenic diseases that are often caused by a single genetic defect. Such diseases are often difficult to treat and have no effective therapies. Therefore, gene therapies can be a promising option to help patients with these diseases. Passage Bio currently has four gene therapy candidates in its pipeline, all focusing on rare neurological diseases. The first candidate, PBGM01, aims to treat GM1 gangliosidosis, a genetic disorder that leads to impairment of the nervous system and often severe impairment of intellectual and physical development. The other candidates focus on treating diseases such as Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type A. Passage Bio has also partnered with Catalent to support the manufacturing and packaging of its gene therapy products. The two companies are working together to develop a scalable production platform for gene therapy manufacturing, which will enable Passage Bio to produce and distribute therapies on a large scale. Overall, Passage Bio has the potential to change the lives of many patients with rare diseases. By developing gene therapies based on AAV technology, the company can create a promising therapy option for patients who currently have no other options available. With a dedicated team of researchers and development specialists, the company is working hard to develop new gene therapies that can contribute to the relief and cure of rare and serious diseases. Passage Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Passage Bio's Return on Capital Employed (ROCE)
Passage Bio's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Passage Bio's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Passage Bio's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Passage Bio’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Passage Bio stock
How has the ROCE (Return on Capital Employed) of Passage Bio developed compared to the previous year?
The ROCE of Passage Bio has increased by 34.63% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Passage Bio?
A high Return on Capital Employed (ROCE) indicates that Passage Bio has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Passage Bio?
A low ROCE (Return on Capital Employed) can indicate that Passage Bio has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Passage Bio impact the company?
An increase in the ROCE of Passage Bio can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Passage Bio affect the company?
A decrease in ROCE of Passage Bio can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Passage Bio?
Some factors that can affect Passage Bio's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Passage Bio so important for investors?
The ROCE of Passage Bio is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Passage Bio take to improve the ROCE?
To improve the ROCE, Passage Bio can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Passage Bio pay?
Over the past 12 months, Passage Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Passage Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Passage Bio?
The current dividend yield of Passage Bio is .
When does Passage Bio pay dividends?
Passage Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Passage Bio?
Passage Bio paid dividends every year for the past 0 years.
What is the dividend of Passage Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Passage Bio located?
Passage Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Passage Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Passage Bio from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Passage Bio pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Passage Bio in the year 2023?
In the year 2023, Passage Bio distributed 0 USD as dividends.
In which currency does Passage Bio pay out the dividend?
The dividends of Passage Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Passage Bio
Our stock analysis for Passage Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Passage Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
